212 related articles for article (PubMed ID: 26990859)
1. Synthesis and anticancer activity of carbosilane metallodendrimers based on arene ruthenium(ii) complexes.
Maroto-Díaz M; Elie BT; Gómez-Sal P; Pérez-Serrano J; Gómez R; Contel M; Javier de la Mata F
Dalton Trans; 2016 Apr; 45(16):7049-66. PubMed ID: 26990859
[TBL] [Abstract][Full Text] [Related]
2. Cyclopentadienyl ruthenium(II) carbosilane metallodendrimers as a promising treatment against advanced prostate cancer.
Sanz Del Olmo N; Bajo AM; Ionov M; García-Gallego S; Bryszewska M; Gómez R; Ortega P; de la Mata FJ
Eur J Med Chem; 2020 Aug; 199():112414. PubMed ID: 32438200
[TBL] [Abstract][Full Text] [Related]
3. Carbosilane metallodendrimers based on copper (II) complexes: Synthesis, EPR characterization and anticancer activity.
Sanz Del Olmo N; Maroto-Díaz M; Gómez R; Ortega P; Cangiotti M; Ottaviani MF; de la Mata FJ
J Inorg Biochem; 2017 Dec; 177():211-218. PubMed ID: 29031179
[TBL] [Abstract][Full Text] [Related]
4. Regulating the anticancer properties of organometallic dendrimers using pyridylferrocene entities: synthesis, cytotoxicity and DNA binding studies.
Govender P; Riedel T; Dyson PJ; Smith GS
Dalton Trans; 2016 Jun; 45(23):9529-39. PubMed ID: 27193373
[TBL] [Abstract][Full Text] [Related]
5. Ruthenium dendrimers against acute promyelocytic leukemia:
Michlewska S; Ionov M; Maroto-Díaz M; Szwed A; Ihnatsyeu-Kachan A; Abashkin V; Dzmitruk V; Rogalska A; Denel M; Gapinska M; Shcharbin D; Gomez Ramirez R; de la Mata FJ; Bryszewska M
Future Med Chem; 2019 Jul; 11(14):1741-1756. PubMed ID: 31287722
[TBL] [Abstract][Full Text] [Related]
6. Organometallic dendrimers based on Ruthenium(II) N-heterocyclic carbenes and their implication as delivery systems of anticancer small interfering RNA.
Rodríguez-Prieto T; Michlewska S; Hołota M; Ionov M; de la Mata FJ; Cano J; Bryszewska M; Gómez R
J Inorg Biochem; 2021 Oct; 223():111540. PubMed ID: 34273717
[TBL] [Abstract][Full Text] [Related]
7. Dimetallic Ru(II) arene complexes appended on bis-salicylaldimine induce cancer cell death and suppress invasion via p53-dependent signaling.
Rahman FU; Bhatti MZ; Ali A; Duong HQ; Zhang Y; Ji X; Lin Y; Wang H; Li ZT; Zhang DW
Eur J Med Chem; 2018 Sep; 157():1480-1490. PubMed ID: 30282320
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, characterization and biological evaluation of novel Ru(II)-arene complexes containing intercalating ligands.
Nikolić S; Rangasamy L; Gligorijević N; Aranđelović S; Radulović S; Gasser G; Grgurić-Šipka S
J Inorg Biochem; 2016 Jul; 160():156-65. PubMed ID: 26818702
[TBL] [Abstract][Full Text] [Related]
9. Derivation of structure-activity relationships from the anticancer properties of ruthenium(II) arene complexes with 2-aryldiazole ligands.
Martínez-Alonso M; Busto N; Jalón FA; Manzano BR; Leal JM; Rodríguez AM; García B; Espino G
Inorg Chem; 2014 Oct; 53(20):11274-88. PubMed ID: 25302401
[TBL] [Abstract][Full Text] [Related]
10. Cellular delivery of pyrenyl-arene ruthenium complexes by a water-soluble arene ruthenium metalla-cage.
Furrer MA; Schmitt F; Wiederkehr M; Juillerat-Jeanneret L; Therrien B
Dalton Trans; 2012 Jun; 41(24):7201-11. PubMed ID: 22506276
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of cytotoxicity by combining pyrenyl-dendrimers and arene ruthenium metallacages.
Pitto-Barry A; Zava O; Dyson PJ; Deschenaux R; Therrien B
Inorg Chem; 2012 Jul; 51(13):7119-24. PubMed ID: 22716166
[TBL] [Abstract][Full Text] [Related]
12. Heterofunctional ruthenium(II) carbosilane dendrons, a new class of dendritic molecules to fight against prostate cancer.
Sanz Del Olmo N; Maroto-Diaz M; Quintana S; Gómez R; Holota M; Ionov M; Bryszewska M; Carmena MJ; Ortega P; Javier de la Mata F
Eur J Med Chem; 2020 Dec; 207():112695. PubMed ID: 32882608
[TBL] [Abstract][Full Text] [Related]
13. Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts.
Chen H; Parkinson JA; Parsons S; Coxall RA; Gould RO; Sadler PJ
J Am Chem Soc; 2002 Mar; 124(12):3064-82. PubMed ID: 11902898
[TBL] [Abstract][Full Text] [Related]
14. Phenanthroline ligands are biologically more active than their corresponding ruthenium(II) arene complexes.
Valladolid J; Hortigüela C; Busto N; Espino G; Rodríguez AM; Leal JM; Jalón FA; Manzano BR; Carbayo A; García B
Dalton Trans; 2014 Feb; 43(6):2629-45. PubMed ID: 24327227
[TBL] [Abstract][Full Text] [Related]
15. Arene ruthenium complexes as anticancer agents.
Süss-Fink G
Dalton Trans; 2010 Feb; 39(7):1673-88. PubMed ID: 20449402
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Characterization of FITC Labelled Ruthenium Dendrimer as a Prospective Anticancer Drug.
Michlewska S; Kubczak M; Maroto-Díaz M; Sanz Del Olmo N; Ortega P; Shcharbin D; Gomez Ramirez R; Javier de la Mata F; Ionov M; Bryszewska M
Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31450702
[TBL] [Abstract][Full Text] [Related]
17.
Gopalakrishnan D; Saravanan S; Merckx R; Madan Kumar A; Khamrang T; Velusamy M; Vasanth K; Sunitha S; Hoogenboom R; Maji S; Ganeshpandian M
Dalton Trans; 2021 Jun; 50(23):8232-8242. PubMed ID: 34037018
[TBL] [Abstract][Full Text] [Related]
18. Exploring the Interactions of Ruthenium (II) Carbosilane Metallodendrimers and Precursors with Model Cell Membranes through a Dual Spin-Label Spin-Probe Technique Using EPR.
Carloni R; Sanz Del Olmo N; Ortega P; Fattori A; Gómez R; Ottaviani MF; García-Gallego S; Cangiotti M; de la Mata FJ
Biomolecules; 2019 Sep; 9(10):. PubMed ID: 31569790
[TBL] [Abstract][Full Text] [Related]
19. Tuning the cytotoxic properties of new ruthenium(III) and ruthenium(II) complexes with a modified bis(arylimino)pyridine Schiff base ligand using bidentate pyridine-based ligands.
Garza-Ortiz A; Maheswari PU; Lutz M; Siegler MA; Reedijk J
J Biol Inorg Chem; 2014 Jun; 19(4-5):675-89. PubMed ID: 24430199
[TBL] [Abstract][Full Text] [Related]
20. Dual-targeting organometallic ruthenium(II) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands.
Zhang Y; Zheng W; Luo Q; Zhao Y; Zhang E; Liu S; Wang F
Dalton Trans; 2015 Aug; 44(29):13100-11. PubMed ID: 26106875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]